<PAGE> 1
FORM 8-K
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 15, 2000
DUSA PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
NEW JERSEY 0-19777 22-3103129
(State or other (IRS Employer
jurisdiction of (Commission Identification
incorporation) File Number) Number)
25 UPTON DRIVE
WILMINGTON, MASSACHUSETTS 01887
(Address of principal executive offices, including ZIP code)
(978) 657-7500
(Registrant's telephone number, including area code)
<PAGE> 2
ITEM 5. OTHER EVENTS.
The Registrant, DUSA Pharmaceuticals, Inc., ("DUSA"), has reported that
it held its Annual Meeting of Shareholders today at DUSA's Wilmington,
Massachusetts headquarters. Dr. D. Geoffrey Shulman, President and CEO, and the
rest of the management team reviewed the accomplishments of the past year, and
updated shareholders on the outlook for the remainder of this year. Dr. Shulman
noted that the launch of DUSA's first product, the Levulan(R) Kerastick(TM) 20%
Topical Solution with the BLU-U(TM) for Photodynamic Therapy to treat
non-hyperkeratotic actinic keratoses of the face and scalp, which was
originally expected in June, 2000, should occur shortly but unlikely to occur
during the balance of this month. DUSA is awaiting review by the FDA of the PMA
Supplement for the commercial version of its BLU-U(TM) and inspection of its
Wilmington facilities which is now being scheduled.
Except for historical information, this report, including the exhibit
contains certain forward-looking statements that involve known and unknown risk
and uncertainties, which may cause actual results to differ materially from any
future results, performance or achievements expressed or implied by the
statements made. These forward-looking statements relate to expectations
regarding the launch of DUSA's first product. Such risks and uncertainties
include, but are not limited to the regulatory approval process, dependence upon
third-party manufacturers of the Kerastick(TM) and the BLU-U(TM), the timing of
the launch by Berlex Laboratories, Inc., the U.S. affiliate of Schering AG, of
Levulan(R) PDT, ability to develop a market for the products, and other risks
identified in DUSA's SEC filings from time to time.
ITEM 7. FINANCIAL STATEMENTS AND OTHER EXHIBITS.
(c) Exhibits.
[99.1] Press Release dated June 15, 2000.
<PAGE> 3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
DUSA PHARMACEUTICALS, INC.
Dated: June 15, 2000 By: /s/ D. Geoffrey Shulman
------------- -----------------------
D. Geoffrey Shulman, MD, FRCPC
President, Chief Executive Officer,
and Chief Financial Officer
